Point of Care Diagnosis of Vaginal Infections to Ensure Accurate Treatment: (PAT Study)

Status: Completed
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Vaginal infections are a common gynecologic issue and may cause significant symptoms and discomfort for individuals. Point of care tests are used to diagnose infections in the office, with an advantage of quick diagnosis and treatment. Examples of point of care tests are urine pregnancy, rapid strep and COVID-19 tests. This study will enroll persons with vaginal complaints and compare diagnosis and treatment based on usual care to diagnosis and treatment using a Food and Drug Administration-approved point of care test for the diagnosis of vaginitis. The study is being done to better understand diagnosis, treatment, and satisfaction using point of care tests compared to usual care. Participants will be randomized to one of two study arms: Arm 1: the healthcare provider will perform their usual evaluation and tests to make the diagnosis and provide treatment, as needed. Arm 2: the provider will be asked to use the results of the point-of-care test being used in the study to make the diagnosis and provide treatment, as needed. Regardless of arm, all diagnoses and treatment will be provided through the healthcare provider. All participants will be contacted 2 weeks later to answer a questionnaire related to diagnosis, treatment, current symptoms, and satisfaction with their visit. Medical records related to vaginal complaints, up to 30 days from enrollment, will be reviewed by the study team to obtain information on symptoms, tests performed, results, and treatments prescribed.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 14
Healthy Volunteers: f
View:

• Complaining of at least one symptom of vaginitis: vaginal discharge, vaginal odor, vulvar or vaginal itch. Women having vulvar or vaginal discomfort such as irritation, burning, pain of less than 2 months duration are also eligible. Pregnant participants who complain of vaginal discharge will be required to have at least one additional vaginal symptom to be eligible.

• Seeking care at one of the participating offices.

• Able and willing to provide informed consent.

• Willing to undergo all study-related assessments and procedures, including self-collection of vaginal swabs, answering questions/surveys, agreeing to the review and collection of information from their medical record from the office (enrollment/index) visit and up to 4 weeks after the office visit.

• Able and willing to provide informed consent

• Provided clinical care to at least one study participant on the date of their study enrollment

• Willing to undergo all study-related assessments including answering questions/surveys

Locations
United States
Pennsylvania
Magee-Womens Hospital of UPMC
Pittsburgh
Time Frame
Start Date: 2024-06-16
Completion Date: 2025-03-26
Participants
Target number of participants: 276
Treatments
Other: Usual Care
Vaginitis diagnosis and treatment will be based on usual provider evaluation and treatment during the office visit
Other: Same Day Results
the Xpert® Xpress MVP test will be run in real time as a point of care test at the time of the office visit and the results will be made available to the provider in approximately one hour. Providers will be asked to use the MVP test result for diagnosis and treatment of the participant.
Related Therapeutic Areas
Sponsors
Collaborators: Cepheid
Leads: Sharon L Hillier

This content was sourced from clinicaltrials.gov